Synapse Medicine closes €7 million round for drug safety platform

Synapse Medicine, the medical intelligence platform developer, has raised €7 million in a round led by MACSF, a French insurance provider for healthcare professionals. The funds will be used to continue development of the company’s platform.

The potential for harm from taking medication is a problem that leads to hundreds of thousands of hospitalisations every year. The company’s SaaS platform gives healthcare professionals such as doctors and pharmacists an easy way to look up reliable, up-to-date information about medications, to analyse prescriptions in real-time, and to ensure the safety of drug therapies. The platform has been integrated into telehealth services, and there is also a version for use by the general public.

This new round of funding will enable Synapse to expand globally, taking advantage of the fast-growing telehealth sector. Its solution allows telehealth companies to enhance their services with a prescription solution that ensures the safety of prescriptions, providing added value to both physicians and patients.

Founded in 2017 by Dr Clément Goehrs, Dr Louis Létinier and Bruno Thiao-Layel, Synapse Medicine is a spin-off from Centre Hospitalier Universitaire de Bordeaux in France. The company raised a seed round of €2.5 million in March 2019. The latest round brings total funding to over €10 million from MACSF, XAnge, Kima Ventures, BNP Paribas, BPI France, the Nouvelle-Aquitaine region, and various angel investors.